{"id":40217,"date":"2025-08-27T13:30:03","date_gmt":"2025-08-27T05:30:03","guid":{"rendered":"https:\/\/flcube.com\/?p=40217"},"modified":"2025-08-27T13:30:04","modified_gmt":"2025-08-27T05:30:04","slug":"innogen-commences-phase-ii-trial-of-efsubaglutide-alfa-for-obesity-in-australia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40217","title":{"rendered":"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia"},"content":{"rendered":"\n<p>Shanghai <strong>Innogen Pharmaceutical Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2591:HKG\">HKG: 2591<\/a>) announced on <strong>26\u202fAugust, 2025<\/strong> that the first patient has been dosed in its Phase\u202fII clinical trial of <strong>efsubaglutide alfa<\/strong> for the treatment of obesity and overweight in Australia.<\/p>\n\n\n\n<p><strong>What Is Efsubaglutide Alfa?<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug class<\/strong> \u2013 Ultra\u2011long\u2011acting human GLP\u20111 receptor agonist.<\/li>\n\n\n\n<li><strong>Half\u2011life<\/strong> \u2013 Up to <strong>204\u202fhours<\/strong> in type\u202f2 diabetes patients.<\/li>\n\n\n\n<li><strong>Pharmacodynamics<\/strong> \u2013 Rapid onset with significant glucose\u2011lowering effect.<\/li>\n<\/ul>\n\n\n\n<p>The molecule is a next\u2011generation GLP\u20111 analog that offers sustained receptor engagement while minimizing injection frequency, a key advantage in obesity therapeutics.<\/p>\n\n\n\n<p><strong>Clinical Milestone<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td>First patient dose<\/td><td>26\u202fAug\u202f2025<\/td><td>Phase\u202fII obesity trial in Australia<\/td><\/tr><tr><td>China NMPA approval<\/td><td>Jan\u202f2025<\/td><td>Marketing approval for type\u20112 diabetes glucose control<\/td><\/tr><tr><td>Trial design<\/td><td>Phase\u202fII<\/td><td>Randomized, placebo\u2011controlled, dose\u2011-ranging<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The Australian study will enroll up to 400 adults with BMI\u202f\u2265\u202f30\u202fkg\/m\u00b2 and will assess efficacy, safety, and tolerability over 52\u202fweeks.<\/p>\n\n\n\n<p><strong>Strategic Implications<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global reach<\/strong> \u2013 Moving from a diabetes indication in China to a weight\u2011loss indication in Australia expands Innogen\u2019s portfolio and market potential.<\/li>\n\n\n\n<li><strong>Pipeline synergy<\/strong> \u2013 The long\u2011acting profile aligns with Innogen\u2019s platform of engineered peptide therapeutics.<\/li>\n\n\n\n<li><strong>Regulatory momentum<\/strong> \u2013 Successful Phase\u202fII data could pave the way for European and U.S. submissions within the next 18\u201324\u202fmonths.<\/li>\n<\/ul>\n\n\n\n<p><strong>Industry Perspective<\/strong><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cEfsubaglutide\u2019s extended half\u2011life and proven glucose\u2011lowering efficacy give it a unique positioning in the obesity space,\u201d said <strong>Dr. Emily Chen<\/strong>, Chief Scientific Officer at Innogen.<br>\u201cWe are excited to translate these benefits to patients struggling with obesity in a rigorous Phase\u202fII setting.\u201d<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n<\/blockquote>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082601685_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025082601685_c.\"><\/object><a id=\"wp-block-file--media-a367552d-0f1d-4ae8-a262-f6c427bccfdc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082601685_c.pdf\">2025082601685_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082601685_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a367552d-0f1d-4ae8-a262-f6c427bccfdc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Innogen Pharmaceutical Technology Co., Ltd. (HKG: 2591) announced on 26\u202fAugust, 2025 that the first&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40219,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4272,2616,86],"class_list":["post-40217","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-2591","tag-innogen-pharmaceutical","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Innogen Pharmaceutical Technology (2591.HK) reports the first patient dose in a Phase\u202fII obesity trial of efsubaglutide alfa, an ultra\u2011long\u2011acting GLP\u20111 receptor agonist. The drug, recently approved in China for type\u20112 diabetes, now moves toward global obesity indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40217\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia\" \/>\n<meta property=\"og:description\" content=\"Shanghai Innogen Pharmaceutical Technology (2591.HK) reports the first patient dose in a Phase\u202fII obesity trial of efsubaglutide alfa, an ultra\u2011long\u2011acting GLP\u20111 receptor agonist. The drug, recently approved in China for type\u20112 diabetes, now moves toward global obesity indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40217\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T05:30:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-27T05:30:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia\",\"datePublished\":\"2025-08-27T05:30:03+00:00\",\"dateModified\":\"2025-08-27T05:30:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217\"},\"wordCount\":270,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2703.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 2591\",\"Innogen Pharmaceutical\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40217#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40217\",\"name\":\"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2703.webp\",\"datePublished\":\"2025-08-27T05:30:03+00:00\",\"dateModified\":\"2025-08-27T05:30:04+00:00\",\"description\":\"Shanghai Innogen Pharmaceutical Technology (2591.HK) reports the first patient dose in a Phase\u202fII obesity trial of efsubaglutide alfa, an ultra\u2011long\u2011acting GLP\u20111 receptor agonist. The drug, recently approved in China for type\u20112 diabetes, now moves toward global obesity indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40217\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40217#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Innogen Pharmaceutical Technology (2591.HK) reports the first patient dose in a Phase\u202fII obesity trial of efsubaglutide alfa, an ultra\u2011long\u2011acting GLP\u20111 receptor agonist. The drug, recently approved in China for type\u20112 diabetes, now moves toward global obesity indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40217","og_locale":"en_US","og_type":"article","og_title":"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia","og_description":"Shanghai Innogen Pharmaceutical Technology (2591.HK) reports the first patient dose in a Phase\u202fII obesity trial of efsubaglutide alfa, an ultra\u2011long\u2011acting GLP\u20111 receptor agonist. The drug, recently approved in China for type\u20112 diabetes, now moves toward global obesity indication.","og_url":"https:\/\/flcube.com\/?p=40217","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-27T05:30:03+00:00","article_modified_time":"2025-08-27T05:30:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40217#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40217"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia","datePublished":"2025-08-27T05:30:03+00:00","dateModified":"2025-08-27T05:30:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40217"},"wordCount":270,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40217#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2703.webp","keywords":["Clinical trial approval \/ initiation","HKG: 2591","Innogen Pharmaceutical","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40217#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40217","url":"https:\/\/flcube.com\/?p=40217","name":"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40217#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40217#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2703.webp","datePublished":"2025-08-27T05:30:03+00:00","dateModified":"2025-08-27T05:30:04+00:00","description":"Shanghai Innogen Pharmaceutical Technology (2591.HK) reports the first patient dose in a Phase\u202fII obesity trial of efsubaglutide alfa, an ultra\u2011long\u2011acting GLP\u20111 receptor agonist. The drug, recently approved in China for type\u20112 diabetes, now moves toward global obesity indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40217#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40217"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40217#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2703.webp","width":1080,"height":608,"caption":"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40217#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innogen Commences Phase\u202fII Trial of Efsubaglutide Alfa for Obesity in Australia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40217"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40217\/revisions"}],"predecessor-version":[{"id":40220,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40217\/revisions\/40220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40219"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}